Italia markets closed

Sutro Biopharma, Inc. (STRO)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
5,65+0,72 (+14,60%)
Alla chiusura: 04:00PM EDT
5,55 -0,10 (-1,77%)
Dopo ore: 07:59PM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente4,93
Aperto4,97
Denaro5,64 x 200
Lettera5,70 x 200
Min-Max giorno4,97 - 6,13
Intervallo di 52 settimane2,01 - 6,13
Volume3.123.359
Media Volume943.316
Capitalizzazione344,386M
Beta (5 anni mensile)0,95
Rapporto PE (ttm)N/D
EPS (ttm)-1,78
Prossima data utili13 mag 2024 - 17 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A13,78
  • GlobeNewswire

    Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023. Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs,

  • GlobeNewswire

    Sutro Biopharma to Participate in Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences. Presentation Details: Citi 18th Annual BioPharma ConferenceFormat: Fireside ChatDate: Wednesday, September 6, 2023Time: 8:00 a.m. ET / 5:00 a.m. PT Locat

  • GlobeNewswire

    Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

    - Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant ovarian cancer - - Sutro will present data from the Phase 1 dose expansion for luvelta for patients with endometrial cancers as a Mini Oral Session at ESMO 2023 - - Sutro announced a royalty monetization agreement with Blackstone Life Sciences in June 2023, under which Sutro received an upfront payment of $140 million, and is eligible to receive up to a